NEW YORK (GenomeWeb) – When the choice is whether to prescribe patients experimental, targeted drugs based on genetic markers driving their tumors, or recommend immunotherapies, doctors are often going with the latter, a recent survey found.

A sampling of more than 100 physicians showed that more than two-thirds preferred prescribing patients a type of immunotherapy, called a checkpoint inhibitor, rather than direct them to an experimental targeted drug based on genomic testing.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.